10-K/A: NovaBay Pharmaceuticals Files Amended 10-K to Include Missing Exhibit

NovaBay Pharmaceuticals has filed an amendment to its annual report on Form 10-K to include a previously omitted exhibit, with no other changes made to the original filing.

Summary

• NovaBay Pharmaceuticals filed an amendment, Form 10-K/A, to its annual report for the fiscal year ended December 31, 2023.
• The amendment was made to include Exhibit 4.1, the Description of Securities, which was inadvertently omitted from the original filing on March 26, 2024.
• No other changes were made to the original filing, and the amendment does not reflect events occurring after March 26, 2024.
• The company's common stock is traded on the NYSE American under the symbol NBY.
• As of March 21, 2024, there were 30,098,150 shares of the company's common stock outstanding.
• The aggregate market value of voting stock held by non-affiliates as of June 30, 2023, was approximately $3,050,485.

Sentiment

Score: 6

Explanation: The document is a routine regulatory filing with a minor correction, so the sentiment is neutral. The need for an amendment is slightly negative, but the company has taken corrective action.

Positives

• The company has taken corrective action to rectify an omission in its original filing.
• The company is adhering to regulatory requirements by filing the amendment.

Negatives

• The need for an amendment indicates a potential oversight in the initial filing process.

Risks

• The omission of an exhibit, while corrected, could raise concerns about the company's internal controls and reporting procedures.
• The amendment does not address any events occurring after the original filing date, which could mean that the information is not fully up to date.

Future Outlook

The amendment does not include any forward-looking statements or guidance.

Management Comments

• Justin Hall, Chief Executive Officer, certified that the report does not contain any untrue statement of a material fact or omit to state a material fact.
• Tommy Law, Interim Chief Financial Officer, certified that the report does not contain any untrue statement of a material fact or omit to state a material fact.

Industry Context

This filing is a routine regulatory requirement for publicly traded companies and the amendment is a correction of an error in the original filing.

Comparison to Industry Standards

• The filing of an amended 10-K to correct an omission is not uncommon, but it does highlight the importance of thoroughness in financial reporting.
• Other companies in the pharmaceutical sector also file similar reports, and the need for amendments can vary based on the complexity of their operations and reporting requirements.
• The market value of non-affiliate holdings is relatively low compared to larger pharmaceutical companies, indicating NovaBay's smaller market capitalization.

Stakeholder Impact

• Shareholders may be concerned about the initial omission, but the company's prompt action to correct it should be reassuring.
• The amendment has no direct impact on employees, customers, suppliers, or creditors.

Key Dates

Keywords

Form 10-K/A, amendment, securities, filing, NovaBay Pharmaceuticals, financial reporting, NYSE American, NBY